Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ImmVira Approved to Start Trials of Oncolytic Virus Candidate for Malignant Glioma

publication date: Mar 30, 2023

Shenzhen ImmVira, a company developing biological vectors as a delivery mechanism, was approved to start China trials of its oncolytic virus product MVR-C5252 in patients with malignant glioma. The company will also conduct clinical research on the candidate with Duke University in the US using Convection Enhanced Delivery as the administration method. Developed on ImmVira's OVPENS platform, MVR-C5252 is designed to treat central nervous system tumors. ImmVira’s first three oncolytic virus products are undergoing six Phase I or Phase II clinical trials in the US and China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here